# Corbus Pharmaceuticals Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Corbus Pharmaceuticals Holdings, Inc.). ## Overview Corbus Pharmaceuticals Holdings, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies in oncology and obesity. Its pipeline centers on CRB-701, an antibody-drug conjugate targeting Nectin-4 in cancer, and CRB-913, a peripherally restricted CB1 receptor inverse agonist designed for obesity treatment. ## Products & services • CRB-701 next-generation ADC for Nectin-4-expressing cancers • CRB-913 peripherally restricted CB1 inverse agonist for obesity • CRB-601 monoclonal antibody in preclinical/clinical manufacturing • Clinical development and translational research programs • Drug manufacturing oversight through third-party contract manufacturers - **Oncology pipeline** (50%) — Includes CRB-701 and related cancer-focused development programs targeting solid tumors. - **Obesity pipeline** (30%) — Includes CRB-913, a CB1 receptor program aimed at weight-loss treatment. - **Preclinical antibody programs** (15%) — Includes CRB-601 and other early-stage biologics under development. - **Research and development services** (5%) — Internal R&D, clinical operations, and regulatory development activities supporting the pipeline. - CRB-701 next-generation ADC for Nectin-4-expressing cancers - CRB-913 peripherally restricted CB1 inverse agonist for obesity - CRB-601 monoclonal antibody in preclinical/clinical manufacturing - Clinical development and translational research programs - Drug manufacturing oversight through third-party contract manufacturers ## Customers Corbus does not currently sell commercial products, so its near-term 'customers' are primarily clinical investigators, trial sites, regulators, and future licensing or commercialization partners. If approved, its therapies would be used by oncology and obesity patients through physicians and healthcare systems, but today the business is funded by capital markets rather than product buyers. - **Clinical trial ecosystem** (primary) — Hospitals, investigators, and CROs that support enrollment, dosing, monitoring, and data collection for CRB-701, CRB-913, and CRB-601. - **Regulatory authorities** (primary) — FDA and comparable agencies that determine whether product candidates can advance to later-stage trials or approval. - **Pharma development partners** (secondary) — Potential licensing or collaboration partners that may fund development, share risk, or commercialize assets. - **Future oncology prescribers** (emerging) — Oncologists who would prescribe CRB-701 if it reaches approval and demonstrates clinical benefit. - **Future obesity prescribers** (emerging) — Physicians treating obesity who could adopt CRB-913 if safety and efficacy are validated. - Clinical trial sites and investigators running Corbus studies - Regulators reviewing INDs, safety data, and marketing applications - Future pharma partners for licensing, co-development, or commercialization - Oncology patients and physicians as eventual end-market users - Obesity patients and prescribers as eventual end-market users ## Geography Corbus is headquartered in Norwood, Massachusetts and operates as a U.S.-based clinical-stage company. The reports indicate most cash and operating activity are concentrated in the United States, while clinical development and regulatory interactions can extend to other countries through trials, vendors, and future commercialization pathways. - Headquartered in Norwood, Massachusetts, United States - Most cash and operating resources are held in the U.S. - Clinical trials may involve sites and vendors outside the U.S. - No country revenue disclosure because the company has no product sales - Future commercialization could broaden exposure beyond the U.S. ## Strategy Corbus is focused on advancing a small number of high-conviction pipeline assets rather than managing a broad commercial portfolio. Near-term strategy is to progress CRB-701 and CRB-913 through clinical development, maintain manufacturing readiness through third parties, and secure additional financing to fund multi-year development work. - **Advance CRB-701 clinical development** (short-term) — The oncology asset is a core value driver and needs human data to support partnering or later-stage trials. - **Progress CRB-913 obesity program** (short-term) — The obesity market is large, but the program must prove safety and tolerability to differentiate from competitors. - **Secure external funding** (short-term) — The company has no product revenue and expects continued operating losses, so capital access is essential. - Advance CRB-701 through clinical development in oncology - Progress CRB-913 Phase 1 obesity studies and safety profiling - Build manufacturing and supply capability through contract partners - Seek collaborations, grants, or capital to fund development - Preserve cash while prioritizing the highest-value pipeline assets ## Risks Corbus is exposed to the classic risks of an early-stage biotech: no product revenue, high cash burn, and uncertainty that clinical candidates will succeed or reach approval. Its dependence on third-party manufacturers, CROs, and regulators means delays or quality issues can materially slow development, while competition in both oncology and obesity is intense. - **Lack of product revenue** [critical] — The company has not commercialized any products, so value depends on future clinical and regulatory success. - **Funding and dilution risk** [high] — Ongoing R&D and clinical costs require repeated capital raises, which may be unavailable or dilutive. - **Clinical development failure** [high] — Drug candidates may not show sufficient safety or efficacy in trials, which would impair commercialization prospects. - **Third-party manufacturing and trial execution** [high] — The company relies on external manufacturers and service providers to produce clinical material and run studies. - **Competitive pressure** [medium] — Larger biopharma companies and other biotech firms are pursuing similar oncology and obesity mechanisms. - **Geopolitical and trade exposure** [medium] — Management disclosed that U.S.-China trade relations and broader geopolitical conditions could affect operations and results. - No product revenue and continued operating losses - Need for additional financing may dilute shareholders - Clinical trial failure or delays could halt pipeline value creation - Third-party manufacturing and CRO dependence adds execution risk - Competition is strong in both Nectin-4 ADCs and obesity drugs ## Accounting Corbus has no product revenue, so reported results are driven mainly by R&D, G&A, and financing-related items rather than sales recognition. Investors should watch estimates for accrued R&D, stock-based compensation, fair value of equity-related instruments, and milestone obligations under licensing agreements, because these can materially affect quarterly losses and balance-sheet liabilities. - **Accrued research and development expense** — Can shift expense timing between quarters - **Stock-based compensation** — Affects operating loss and diluted share metrics - **License milestone obligations** — Can create contingent liabilities and cash outflows - **Fair value of cash equivalents and investments** — Affects other income and liquidity presentation - No product revenue recognized; results are driven by operating expenses - Accrued R&D estimates affect timing of clinical expense recognition - Stock-based compensation is a meaningful non-cash expense - License milestones create contingent obligations and liabilities - Cash and investments are subject to fair value and interest income changes --- *Last updated: 2026-04-28T19:59:10.956761+00:00*